Lakefront Biotherapeutics NV current report, Q4 FY2016

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV, a foreign private issuer headquartered in Mechelen, Belgium. The filing covers the month of December 2016, specifically referencing a press release issued on December 8, 2016. The registrant files annual reports on Form 20-F. Note: The request metadata mentions "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as Galapagos NV.

Key Financial Metrics

The filing text does not provide specific financial data. This document serves solely to incorporate a press release by reference and does not contain revenue, profit, cash flow, margins, debt, or liquidity figures.

Material Changes

The filing does not disclose material changes to financial performance or operations. It references an attached press release (Exhibit 99.1) for details on the material event, but the content of that press release is not included in the provided text.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, financial guidance, outlook, risk factors, or details on contingencies and unusual items. These details are presumed to be within the attached Exhibit 99.1, which is not present in the source text.

Investor Verification Checklist

  • Verify the actual content of the press release dated December 8, 2016 (Exhibit 99.1), as the filing text only references it.
  • Confirm the registrant name is Galapagos NV, not Lakefront Biotherapeutics NV.
  • Review the incorporated Registration Statements (Forms F-3 and S-8) for broader context on the company's capital structure.
  • Check subsequent filings for the financial impact of the event described in the December 8 press release.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.